Kumar Nithin, Francis Mariea, Sindhu Vk Sai, Ramachandra Varun, Anilkumar P Vijay, Fahad Khan Mohammad
Department of Oral and Maxillofacial Surgery, School of Dentistry, Central Asian University, Tashkent, UZB.
Department of Oral and Maxillofacial Surgery, Sankalchand Patel University, Visnagar, IND.
Cureus. 2024 Feb 17;16(2):e54367. doi: 10.7759/cureus.54367. eCollection 2024 Feb.
Temporomandibular joint (TMJ) pain is a common condition that can significantly impact an individual's quality of life. Current treatment options often fall short of providing long-lasting relief. So, this prospective clinical study aimed to investigate the efficacy of injectable platelet-rich fibrin (I-PRF) in mitigating TMJ pain.
A total of 68 participants, aged 18-60 years, clinically diagnosed with TMJ pain, were recruited from dental clinics and specialist referrals. Participants were randomly assigned to either the intervention group (I-PRF injections) or the control group (placebo). Primary outcome measures included TMJ pain intensity and jaw function, assessed using the Visual Analog Scale and functional examinations, respectively. Secondary outcomes comprised patient-reported outcomes (PROs) on quality of life and satisfaction. Data were collected at baseline and six, 12, and 24 weeks post intervention.
Baseline characteristics demonstrated successful randomization, with no significant differences in age, gender, or TMJ pain duration between groups. Post intervention, the intervention group exhibited a significant and sustained reduction in TMJ pain intensity compared to controls (p<0.001). Improvements in jaw function were also notable in the intervention group at all follow-up time points (p<0.001). PROs related to quality of life and satisfaction substantially increased in the intervention group compared to controls (p<0.001).
I-PRF demonstrated significant efficacy in reducing TMJ pain intensity, improving jaw function, and enhancing PROs. These findings support the consideration of I-PRF as a valuable therapeutic intervention for individuals with TMJ pain.
颞下颌关节(TMJ)疼痛是一种常见病症,会对个人生活质量产生重大影响。目前的治疗方法往往无法提供持久的缓解。因此,这项前瞻性临床研究旨在调查注射用富血小板纤维蛋白(I-PRF)减轻TMJ疼痛的疗效。
从牙科诊所和专科转诊中招募了68名年龄在18至60岁之间、临床诊断为TMJ疼痛的参与者。参与者被随机分配到干预组(I-PRF注射)或对照组(安慰剂)。主要结局指标包括TMJ疼痛强度和下颌功能,分别使用视觉模拟量表和功能检查进行评估。次要结局包括患者报告的生活质量和满意度结局。在基线以及干预后6周、12周和24周收集数据。
基线特征显示随机分组成功,两组之间在年龄、性别或TMJ疼痛持续时间方面无显著差异。干预后,与对照组相比,干预组的TMJ疼痛强度显著且持续降低(p<0.001)。在所有随访时间点,干预组的下颌功能也有显著改善(p<0.001)。与对照组相比,干预组中与生活质量和满意度相关的患者报告结局大幅增加(p<0.001)。
I-PRF在降低TMJ疼痛强度、改善下颌功能和提高患者报告结局方面显示出显著疗效。这些发现支持将I-PRF视为TMJ疼痛患者的一种有价值的治疗干预措施。